In addition, miR‐9 was identified as potential candidate effector for inhibiting TLR4, and we assessed for the first time the therapeutic efficacy of exosomal miR‐9 derived from MSCs in IC/BPS. Here, TLR4 is linked to Bartsocas-Papas syndrome 1.